Paul Grint

Paul Grint is an experienced executive in the biotechnology and pharmaceutical sectors, currently serving as Executive Chairman at Codagenix Inc. and as a Board Member for multiple organizations including CRISPR QC, INHIBIKASE THERAPEUTICS, INC., and Persephone Biosciences. Since 2019, Paul Grint has held the position of Entrepreneur In Residence at the University of California San Diego. Paul Grint's previous roles include CEO of AmpliPhi Biosciences and President & CEO of Regulus Therapeutics, as well as President of Cerexa, a subsidiary of Forest Labs. Paul Grint also served as Senior Vice President of Early Development and Internal Medicine at Forest Laboratories prior to the leadership roles. Paul Grint holds a Bachelor of Medicine, Bachelor of Surgery (MBBS) from St. Bartholomew's Hospital, University of London, and attended Stowe School.